<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications for treatment of women with urgency urinary incontinence (UUI) or overactive bladder (OAB)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications for treatment of women with urgency urinary incontinence (UUI) or overactive bladder (OAB)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications for treatment of women with urgency urinary incontinence (UUI) or overactive bladder (OAB)</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Starting dose</td> <td class="subtitle1">Maximum dose</td> <td class="subtitle1">Selected characteristics</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Anticholinergics</td> </tr> <tr> <td class="indent1">Darifenacin extended-release<br/> (7.5 and 15 mg tablets)</td> <td>7.5 mg orally once daily</td> <td>15 mg orally once daily</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Metabolized in liver by CYP3A4; maximum 7.5 mg daily with strong CYP3A4 inhibitors<sup>*</sup></li> <li>Reduced dose for moderate hepatic impairment</li> <li>Not recommended for severe hepatic impairment</li> <li>Do not crush, divide, or chew tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Fesoterodine extended-release<br/> (4 and 8 mg tablets)</td> <td>4 mg orally once daily</td> <td>8 mg orally once daily</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Metabolized in liver by CYP3A4; maximum 4 mg daily with strong CYP3A4 inhibitors<sup>*</sup></li> <li>Reduced dose for severe renal impairment</li> <li>Not recommended for severe hepatic impairment</li> <li>Do not crush, divide, or chew tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Oxybutynin immediate-release<br/> (5 mg tablet)</td> <td>5 mg orally 2 or 3 times daily</td> <td>5 mg orally 4 times daily</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Dizziness and somnolence can occur</li> <li>Often not tolerated by older adults and medically ill patients due to anticholinergic (including CNS) side effects</li> <li>Reduced dose in older adults</li> <li>Short effect may be useful when continence is desired at specific times</li> <li>Compliance is difficult with frequent dosing</li> </ul> </td> </tr> <tr> <td class="indent1">Oxybutynin extended-release<br/> (5, 10, and 15 mg tablets)</td> <td>5 to 10 mg orally once daily</td> <td>30 mg orally once daily</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Somnolence (6%) can occur</li> <li>Compliance is improved with daily dosing</li> <li>Do not crush, divide, or chew tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Oxybutynin transdermal<br/> (10% gel sachet [packet] or pump)</td> <td>Apply 1 sachet (packet) or 1 pump once daily; each packet or pump delivers 1 g of gel equivalent to 100 mg oxybutynin</td> <td>Same as starting dose</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Associated with low rates of dry mouth and constipation</li> <li>Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders</li> <li>Keep area dry for at least 1 hour after application</li> <li>Do not use same application site more than once in 7 days</li> <li>Application site reaction including irritation and dermatitis</li> </ul> </td> </tr> <tr> <td class="indent1">Oxybutynin transdermal<br/> (3.9 mg patch)</td> <td>Apply 1 patch twice per week (ie, once every 3 to 4 days)</td> <td>Do not exceed starting dose</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Available without a prescription (OTC) in the United States and some other countries</li> <li>Associated with low rates of dry mouth and constipation</li> <li>Apply under clothing to abdomen, hip, or buttock</li> <li>Do not use same application site more than once in 7 days</li> <li>Application site pruritus; local erythema, rash</li> </ul> </td> </tr> <tr> <td class="indent1">Solifenacin<br/> (5 and 10 mg tablets</td> <td>5 mg orally once daily</td> <td>10 mg orally once daily</td> <td> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Reduce dose for severe renal impairment or moderate hepatic impairment</li> <li>Not recommended for severe hepatic impairment</li> <li>Metabolized in liver by CYP3A4; maximum 5 mg daily with CYP3A4 inhibitors<sup>*</sup></li> <li>Modestly prolongs QTc interval; caution with other QTc prolonging drugs<sup>*</sup> and in patients with congenital prolonged QT</li> <li>Can crush, divide, or chew tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Tolterodine extended-release<br/> (2 and 4 mg tablets)</td> <td>2 mg orally once daily</td> <td>4 mg orally once daily</td> <td rowspan="2"> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Dry mouth and constipation are common</li> <li>Reduced dose for renal and/or hepatic impairment, not recommended for severe renal or hepatic impairment</li> <li>Metabolized in liver by CYPs 3A4 and 2D6; maximum 2 mg daily with strong CYP3A4 inhibitors<sup>*</sup></li> <li>Modestly prolongs QTc interval; caution with other QTc prolonging drugs<sup>*</sup> and in patients with congenital prolonged QT</li> <li>Do not crush, divide, or chew extended-release tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Tolterodine immediate-release<br/> (1 and 2 mg tablets)</td> <td>1 mg orally twice daily</td> <td>2 mg orally twice daily</td> </tr> <tr> <td class="indent1">Trospium extended-release<br/> (60 mg tablet)</td> <td>60 mg orally once daily</td> <td>Same as starting dose</td> <td rowspan="2"> <ul> <li>See "General antimuscarinic issues" below for contraindications, association with dementia, and adverse effects</li> <li>Need to take on empty stomach or 1 hour before meal</li> <li>Dry mouth and constipation are common</li> <li>Reduce dose for renal impairment, not recommended for severe renal impairment</li> <li>Not metabolized by CYP and therefore has a low risk of drug-drug interactions</li> <li>Avoid alcohol consumption within 2 hours of using extended-release preparation</li> <li>Do not crush, divide, or chew extended releases tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Trospium immediate-release<br/> (20 mg tablet)</td> <td>20 mg orally once daily</td> <td>20 mg twice daily</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Beta-3 adrenergic agonists</td> </tr> <tr> <td class="indent1">Mirabegron extended-release (25 and 50 mg tablets)</td> <td rowspan="2">25 mg orally once daily</td> <td rowspan="2">50 mg orally once daily</td> <td rowspan="2"> <ul> <li> Most common side effects include hypertension, nasopharyngitis, urinary tract infection, and headache</li> <li>Associated with increases in heart rate and blood pressure</li> <li>Monitor blood pressure in those with well-controlled and avoid in those with poorly controlled hypertension</li> <li> Metabolized in liver by CYP2D6; when used concomitantly with drugs metabolized by CYP2D6, especially narrow therapeutic index drugs, appropriate monitoring and possible dose adjustment of those drugs may be necessary</li> <li>Reduce dose for renal and hepatic impairment</li> <li>Rare angioedema reactions</li> <li>Minimal (&lt;10mSec) QT interval prolongation</li> <li>Do not crush, divide, or chew tablet</li> </ul> </td> </tr> <tr> <td class="indent1">Liquid granules 8 mg/mL (approved for pediatric dosing only)</td> </tr> <tr> <td class="indent1">Vibegron extended-release (75 mg tablets)</td> <td>75 mg orally once daily</td> <td>Same as starting dose</td> <td> <ul> <li> Most common side effects are headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection</li> <li>No hypertension warnings</li> <li>Does not prolong QT interval</li> <li>Can crush, divide, or chew tablet</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>General antimuscarinic issues:</strong>
<ul class="decimal_heading">
<li>All antimuscarinics are contraindicated in gastric retention, untreated narrow angle closure glaucoma, and supraventricular tachycardia; and should be used with caution in patients with urinary retention and/or obstruction.</li>
<li>Evidence suggests that cumulative exposure to potent antimuscarinics is associated with increased rates of dementia and Alzheimer disease.<sup>[1]</sup></li>
<li>All antimuscarinics exert peripheral anticholinergic effects (eg, dry mouth, constipation, tachycardia, palpitations).</li>
<li>All antimuscarinics may have additive side effects with other medications that have strong anticholinergic effects (eg, first-generation H1 antihistamines, muscle relaxants, tricyclic antidepressants, antipsychotics, inhaled anticholinergic bronchodilators).<sup>*</sup></li>
<li>Approach to agent selection and dose titration is reviewed in the topic section on pharmacologic therapy of urge incontinence.</li>
</ul>
<p class="extra_spacing_top"><strong>General beta-3 adrenergic agonist issues:</strong></p>
<ul class="decimal_heading">
<li>Should be used with caution in patients with urinary retention and/or obstruction.</li>
<li>Patients taking digoxin may need additional monitoring and digoxin dose adjustments.</li>
<li>Should not be used in those with known allergic reaction to drug or components.</li>
<li>Not recommended for severe renal or hepatic impairment.</li>
</ul></div><div class="graphic_footnotes"><p>CNS: central nervous system; CYP: cytochrome P-450 metabolism; OTC: over-the-counter.</p>
* To check for specific interactions, use the Lexi-Interact program included with UpToDate.</div><div class="graphic_reference">Reference:
<ol>
<li>Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: S prospective cohort study. JAMA 2015; 175:401.</li>
</ol></div><div id="graphicVersion">Graphic 99995 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
